Agendia, a developer of genomic-based diagnostic products, has unveiled ColoPrint microarray-based 18-gene expression signature. The ColoPrint assay provides critical additional information for treatment decisions for stage II colon ...
Tags: ColoPrint, Agendia, colon cancer patients
The molecular cancer diagnostics company, Agendia, has introduced ColoPrint microarray-based 18-gene expression assay. The ColoPrint assay is designed for predicting the risk of distant recurrence for stage II colon cancer patients who ...
Tags: molecular cancer diagnostics, expression assay, cancer diagnostics